Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Monoclonal Antibodies in Cancer Therapy 2009-2024

Published by: Visiongain

Published: May. 7, 2009 - 97 Pages


Table of Contents


1 Executive Summary

1.1 Aims of this Report

1.2 Brief Overview of the Chapters in this Report

2 Monoclonal Antibodies for Cancer Therapy

2.1 Oncology is the Fifth-Largest Therapeutic Class Worldwide by Total Sales

2.2 The Oncology Market is Expanding

2.3 Monoclonal Antibodies

2.3.1 What are Monoclonal Antibodies?

2.3.2 How do Monoclonal Antibody Therapies Work?

2.4 Categories of Monoclonal Antibodies for Therapeutic Use

2.4.1 Murine Antibodies

2.4.2 Chimeric and Humanised Antibodies

2.4.3 Human Antibodies

2.4.4 Immunogenicity

2.5 Current Monoclonal Antibody Cancer Therapies

2.5.1 Rituxan/MabThera

2.5.2 Avastin

2.5.3 Herceptin

2.5.4 Erbitux

2.5.5 Vectibix

2.5.6 Campath

2.5.7 Mylotarg

2.5.8 Zevalin and Bexxar

2.5.9 The Market Shares of Naked vs. Conjugated Monoclonal Antibodies 2.5.10 The Market for Monoclonal Antibody Therapies is Growing.

3 Total World Market 2009-2024

3.1 Summary of Key Findings

3.2 Biotech is a Rapidly-Expanding Market

3.3 Monoclonal Antibodies are a Central Part of the Biotech Market

3.4 Oncology - A Major Sales Driver in the Mab Sector

3.5 Total World Market in 2008

3.6 Predicted Sales from 2009-2024

3.7 The Big Three

3.8 Generic Competition

3.9 Chimeric Antibodies in Decline

3.10 The Shift Towards Human Antibodies

4 Key Products Analysis

4.1 Overview: Strong Pipeline Means Competition Will Increase

4.2 Roche/Genentech Dominated the Market in 2008

4.3 Rituxan/MabThera (Roche/Genentech)

4.3.1 Will Rituxan Continue Steady Growth over the Next Five Years?

4.4 Avastin (Roche/Genentech)

4.4.1 Broadened Profile and Patient Base

4.4.2 Continued Growth Despite Competition

4.5 Herceptin (Roche/Genentech)

4.5.1 Strong Competition in the R&D Pipeline

4.6 Erbitux (Merck/Imclone)

4.6.1 Aiming for the Top Three

4.7 Vectibix (Amgen)

4.7.1 The K-RAS Issue

4.8 Campath (Bayer Schering AG)

4.8.1 Future Increase in Revenue?

5 SWOT Analysis for the Monoclonal Antibody Oncology Therapies Market

5.1 Principal Drivers

5.1.1 Increasing Prevalence and High Economic Costs of Cancer

5.1.2 MAb Therapy Presents Lower Risk of Adverse Effects

5.1.3 Combining Existing Products

5.1.4 Biologicals vs. Chemically-Derived Pharmaceutical Products

5.1.5 Promising Pipelines

5.1.6 Improvements in Accessibility

5.1.7 New Production Methods will Reduce Costs

5.2 Principal Restraints

5.2.1 Development Costs - a High Barrier of Entry

5.2.2 Mode of Administration is a Limiting Factor

5.2.3 Insufficient Efficacy as a Single Agent

5.2.4 Immunogenicity - the Rise of Humanised and Human Monoclonal Antibodies

5.2.5 Financial Limitations in Research and Development

5.2.6 Adverse Events - Safety Concerns

5.2.7 Competition for Prime Drug Targets

6 MAbs in the Leading Pharmaceutical Markets

6.1 USA

6.2 Europe

6.3 Other Countries

6.3.1 India and China

7 The Monoclonal Antibody Cancer Therapies Pipeline

7.1 New Technology - Monoclonal Antibody Fragments

7.1.1 Bispecific T-Cell Engagers

7.1.2 Tandabs

7.2 Conjugated vs. Naked Antibodies

7.3 The Future of Human MAbs

7.4 Competition for Prime Drug Targets

7.4.1 Tailored Medicine

7.5 Solid Pipeline

7.6 Products to Watch

7.6.1 Roche's Winning Pipeline

7.6.2 Genmab and GlaxoSmithKline's Arzerra/HuMax-CD20

7.6.3 Amgen's AMG 162

8 Visiongain Interviews with Relevant Experts

8.1 Dr Janice M. Reichert, Tufts University and Editor-in-Chief of the Journal mAbs

8.1.1 Major Challenges and Opportunities for Monoclonal Antibody Cancer Therapies

8.1.2 Future Developments and Pipelines

8.1.3 The Effect of Biosimilars

8.2 Dr David Blakey, AstraZeneca

8.2.1 The Future of Humanised and Fully-Human Antibodies

8.2.2 Therapeutic Antibody Fragments vs. Full-Length IgGs

8.2.3 Major Opportunities in Monoclonal Antibody Cancer Therapies

9 Conclusions

9.1 The MAb Market is Strong and Expected to Grow Stronger

9.2 Expansion into New Markets

9.3 Personalised Treatments Emerging

9.4 Growth Will Eventually Slow as Expansion of the Market Drives Prices Down

9.5 Outlook for the Future


List of Tables

Table 2.1 Summary of Types of Monoclonal Antibodies for Cancer Therapy

Table 2.2 Targets and Indications for Selected FDA-Approved Antibodies

Table 3.1 Top Selling FDA Approved Antibodies, 2008

Table 3.2 Leading Monoclonal Antibodies for Oncology Therapies, Sales ($bn) and Market Shares (%), 2008

Table 3.3 Predicted Sales ($bn) for the World Market, 2009-2024

Table 3.4 Predicted Growth Rate (%) for the World Market, 2009-2024

Table 3.5 World Sales ($bn) and Market Shares (%) for the Different Types of Oncology Monoclonal Antibodies, 2008

Table 3.6 Market Shares (%) for Chimeric, Humanised and Human Monoclonal Antibodies, 2014-2024

Table 4.1 Predicted Sales ($bn) for the World Market, 2009-2016

Table 4.2 Predicted Sales ($bn) for the World Market, 2017-2024

Table 4.3 Market Shares (%) and CAGR (%) for Selected Products, 2008 and 2014

Table 5.1 SWOT Analysis, 2009-2024

Table 5.2 Side Effects of Monoclonal Antibody Therapy Table 6.1 Leading Regions of the Monoclonal Antibody Anticancer Therapies Market, Sales ($bn) and Market Shares (%), 2008 and 2014

Table 7.1 Selected Phase III and Pre-Registration Anticancer Monoclonal Antibodies, 2008 Table 9.1 Global Monoclonal Antibody Anticancer Therapies, Sales ($bn) and Growth (%), 2008-2014


List of Figures

Figure 2.1 Sales ($bn) of Naked vs. Conjugated Monoclonal Antibodies, 2008

Figure 3.1 Market Shares (%) for the Main Categories of the Monoclonal Antibody Market for 12 Months up to Q3 2008

Figure 3.2 Sales ($bn) for the Top Three Monoclonal Antibody Oncology Therapies, 2005-2008 Figure 3.3 Sales ($bn) for Monoclonal Antibody Oncology Therapies for 12 Months up to Q3 2008

Figure 3.4 Market Shares (%) for Monoclonal Antibody Oncology Therapies for 12 Months up to Q3 2008

Figure 3.5 Predicted Sales ($bn) for the World Market, 2009-2024

Figure 3.6 Predicted Growth (%) of the World Market, 2009-2014

Figure 3.7 Predicted Sales ($bn) for the Big Three: Rituxan, Avastin and Herceptin, 2009-2014

Figure 3.8 Sales ($bn) for Different Types of Monoclonal Antibodies for Oncology, 2008 Figure 3.9 Market Shares (%) for Different Types of Monoclonal Antibodies for Oncology, 2008

Figure 3.10 Pipeline Drugs (Phase II and III) by Antibody Type, 2008

Figure 3.11 Predicted Market Shares (%) for Chimeric, Humanised and Human Monoclonal Antibodies, 2014-2024

Figure 4.1 Market Shares (%) for Companies in the Monoclonal Antibody Oncology Therapies Area, 2008

Figure 4.2 Sales ($bn) for Rituxan, 2005-2008

Figure 4.3 Sales ($bn) for Rituxan, 2009-2014

Figure 4.4 Market Share (%) for Rituxan, 2009-2014

Figure 4.5 Sales ($bn) for Rituxan/MabThera, 2009-2024

Figure 4.6 Sales ($bn) for Avastin and Rituxan, 2009-2024

Figure 4.7 Sales ($bn) for Avastin, 2005-2008

Figure 4.8 Market Share (%) for Avastin, 2009-2014

Figure 4.9 Sales ($bn) for Avastin, 2009-2024

Figure 4.10 Sales ($bn) for Herceptin, 2005-2008

Figure 4.11 Sales ($bn) for Herceptin, 2009-2024

Figure 4.12 Market Share (%) for Herceptin, 2008-2014

Figure 4.13 Sales ($bn) for Erbitux, 2005-2008

Figure 4.14 Sales ($bn) for Erbitux, Herceptin and Rituxan, 2009-2024

Figure 4.15 Sales ($bn) for Erbitux, 2009-2024

Figure 4.16 Market Share (%) for Erbitux, 2009-2014

Figure 4.17 Sales ($bn) for Vectibix, 2009-2014

Figure 4.18 Market Share (%) for Vectibix, 2009-2014

Figure 4.19 Sales ($bn) for Vectibix, 2009-2024

Figure 4.20 Sales ($bn) for Campath, 2005-2008

Figure 4.21 Sales ($bn) for Campath, 2009-2024

Figure 4.22 Market Share (%) for Campath, 2009-2014

Figure 6.1 Leading Pharmaceutical Markets, Sales ($bn), 2008, 2014, 2019 and 2024

Figure 6.2 Leading Pharmaceutical Markets, Market Shares (%), 2008, 2014, 2019 and 2024 Figure 6.3 Leading Pharmaceutical Markets, CAGR (%), 2008-2014

Figure 6.4 Comparisons of the US, European, Chinese and Indian Markets, Market Shares (%), 2008-2024

Figure 7.1 Pipeline Drugs (Phase II) by Indication, 2008 Figure 7.2 Pipeline Drugs (Phase III) by Indication, 2008


Abstract

Monoclonal antibodies in cancer therapy - significant commercial opportunities with developing technologies and innovative products - our new report explains prospects

Monoclonal antibody-based therapies for cancer are a thriving part of the biotechnology sector, as our new market report explains. The oncology market continues to expand worldwide, with high demand for more-efficacious and better-tolerated cancer therapies. The monoclonal antibodies oncology market has been growing at a significant rate and holds high potential for continued growth in both developed and emerging geographical markets. Currently, new technologies are removing some of the drawbacks that monoclonal antibody therapies have experienced. Leading pharma companies are already investing heavily in monoclonal antibody technologies. Monoclonal antibodies with great commercial potential are in the oncology pipeline, as our new report - Monoclonal Antibodies in Cancer Therapy 2009-2024 - also explains.

The period 2009 to 2019 will reveal volatility in the monoclonal antibody therapies market as current-leading products reach peak sales and new-generation drugs emerge. Will technological advances further benefit monoclonal antibody-based therapies and their overall sales? Will better immunotoxicity profiles lead to higher revenues for products? What types of monoclonal antibody therapies will enter the market from 2009 onwards, and can they dominate this market? Where will the opportunities lie, and what are the market drivers and restraints? This report will provide you with the information that you need to understand current trends and future possibilities. In particular, we discuss prospects for the following products:
  • Rituxan
  • Avastin
  • Herceptin
  • Erbitux
  • Vectibix
  • Campath.
Comprehensive analysis of this important market area

Monoclonal Antibodies in Cancer Therapy 2009-2024 examines that market sector critically, through a comprehensive review of information sources, including consultations with relevant experts. This report provides detailed sales forecasts, discussions of pipeline developments and analysis of commercial drivers and restraints, including a SWOT analysis. There are over 55 tables and figures included. The result is a comprehensive market- and industry-centred report with detailed analyses and informed opinion.

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009